CBIO Crescent Biopharma, Inc.
Crescent Biopharma, Inc. (CBIO) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 100% planned / 0% discretionary
Largest single sale: $761.1K.
Where they traded
Last open-market purchase: July 16, 2026 .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Brumm Joshua T | Chief Executive Officer | Sell 10b5-1 | 7,837 | $16.71 | $131.0K | 271,765 −2.8% of holding | |
| McNeill Jonathan | President and COO | Sell 10b5-1 | 3,839 | $16.71 | $64.1K | 134,588 −2.8% of holding | |
| Brumm Joshua T | Chief Executive Officer | Sell 10b5-1 | 1,610 | $17.90 | $28.8K | 279,602 −0.6% of holding | |
| McNeill Jonathan | President and COO | Sell 10b5-1 | 731 | $17.90 | $13.1K | 138,427 −0.5% of holding | |
| Pinkas Jan | Chief Scientific Officer | Sell 10b5-1 | 658 | $17.90 | $11.8K | 21,581 −3% of holding | |
| Im Ellie Eunkyung | Chief Medical Officer | Sell 10b5-1 | 623 | $17.90 | $11.2K | 21,446 −2.8% of holding | |
| Bispham Barbara Harlin | See Remarks | Sell 10b5-1 | 620 | $17.90 | $11.1K | 18,710 −3.2% of holding | |
| Scalzo Richard William | Chief Financial Officer | Sell 10b5-1 | 568 | $17.90 | $10.2K | 19,730 −2.8% of holding | |
| Lynch Ryan | See Remarks | Sell 10b5-1 | 240 | $17.90 | $4.3K | 13,631 −1.7% of holding | |
| Buy | 853,450 | $14.50 | $12.4M | 3,601,316 | |||
| Brumm Joshua T | Chief Executive Officer | Sell 10b5-1 | 42,305 | $17.99 | $761.1K | 281,212 −13.1% of holding | |
| McNeill Jonathan | President and COO | Sell 10b5-1 | 20,549 | $17.99 | $369.7K | 139,158 −12.9% of holding | |
| Pinkas Jan | Chief Scientific Officer | Sell 10b5-1 | 1,288 | $17.99 | $23.2K | 22,239 −5.5% of holding | |
| Im Ellie Eunkyung | Chief Medical Officer | Sell 10b5-1 | 1,219 | $17.99 | $21.9K | 22,069 −5.2% of holding | |
| Bispham Barbara Harlin | See Remarks | Sell 10b5-1 | 1,218 | $17.99 | $21.9K | 19,330 −5.9% of holding | |
| Scalzo Richard William | Chief Financial Officer | Sell 10b5-1 | 1,112 | $17.99 | $20.0K | 20,298 −5.2% of holding | |
| Lynch Ryan | See Remarks | Sell 10b5-1 | 465 | $17.99 | $8.4K | 13,871 −3.2% of holding | |
| Buy | 1,360,000 | $13.41 | $18.2M | 2,747,866 |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.